尽管囊性纤维化患者的胰酶补充剂用量减少，但生长仍得以维持。
Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation.
作者信息
Lowdon J, Goodchild M C, Ryley H C, Doull I J
机构信息
Department of Child Health, University Hospital of Wales, Heath Park, Cardiff.
出版信息
Arch Dis Child. 1998 Apr;78(4):377-8. doi: 10.1136/adc.78.4.377.
Abstract
Twenty one children with cystic fibrosis were advised to decrease their pancreatic enzyme supplement (PES) dose to less than 10,000 units lipase/kg/day. Mean PES dosage was significantly decreased in 15 patients from 18,380 to 8647 units lipase/kg/day. There were no significant changes in energy or fat intake, but there were significant increases in weight SD score, height SD score, and weight/height ratio.
摘要
建议21名囊性纤维化患儿将其胰酶补充剂（PES）剂量降至低于10,000单位脂肪酶/千克/天。15名患者的平均PES剂量从18,380单位脂肪酶/千克/天显著降至8647单位脂肪酶/千克/天。能量或脂肪摄入量没有显著变化，但体重标准差评分、身高标准差评分和体重/身高比均显著增加。
相似文献
1
Maintenance of growth in cystic fibrosis despite reduction in pancreatic enzyme supplementation.尽管囊性纤维化患者的胰酶补充剂用量减少，但生长仍得以维持。
Arch Dis Child. 1998 Apr;78(4):377-8. doi: 10.1136/adc.78.4.377.
2
High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.高剂量胰酶补充剂与囊性纤维化患儿的纤维性结肠病
N Engl J Med. 1997 May 1;336(18):1283-9. doi: 10.1056/NEJM199705013361803.
3
High compared with standard dose lipase pancreatic supplement.与标准剂量的脂肪酶胰腺补充剂相比偏高。
Arch Dis Child. 1989 Jan;64(1):143-5. doi: 10.1136/adc.64.1.143.
4
High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial.囊性纤维化中高与低脂肪酶耐酸酶制剂的比较：一项交叉随机临床试验。
J Pediatr Gastroenterol Nutr. 1996 Jan;22(1):73-8. doi: 10.1097/00005176-199601000-00012.
5
Comparison of weight-based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis.
J Pediatr Gastroenterol Nutr. 1994 Aug;19(2):191-7. doi: 10.1097/00005176-199408000-00009.
6
Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy.纤维化结肠病变前后囊性纤维化患者的胰酶补充治疗
J Pediatr Gastroenterol Nutr. 1998 Jan;26(1):80-4. doi: 10.1097/00005176-199801000-00014.
7
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.补充胰酶对囊性纤维化患儿的疗效：通过随机交叉研究比较两种制剂，并对同一组患者在两个不同年龄进行回顾性研究。
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S40-5.
8
A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis.一项用于比较高活性脂肪酶与标准胰酶制剂在囊性纤维化中脂肪酶活性的双盲研究。
Arch Dis Child. 1993 Feb;68(2):227-30. doi: 10.1136/adc.68.2.227.
9
A comparison of two pancreatin microsphere preparations in cystic fibrosis.囊性纤维化中两种胰酶微球制剂的比较。
N Z Med J. 1992 Mar 25;105(930):107-8.
10
Pancreatic enzyme supplement dosage in cystic fibrosis.
Lancet. 1991 Nov 2;338(8775):1153. doi: 10.1016/0140-6736(91)92017-v.
引用本文的文献
1
Parenteral medication for the management of acute severe behavioural disturbance (ASBD) in the emergency department.用于急诊科急性严重行为障碍（ASBD）管理的胃肠外用药
Cochrane Database Syst Rev. 2024 May 29;5(5):CD014826. doi: 10.1002/14651858.CD014826.
2
Lipid, nitrogen, water and energy content of a single stool sample in healthy children and children with cystic fibrosis.健康儿童和囊性纤维化患儿单次粪便样本中的脂质、氮、水和能量含量。
Eur J Pediatr. 2003 Nov;162(11):764-6. doi: 10.1007/s00431-003-1291-y. Epub 2003 Aug 27.
3
Control of malabsorption in cystic fibrosis.囊性纤维化中吸收不良的控制
Paediatr Drugs. 2000 May-Jun;2(3):205-22. doi: 10.2165/00128072-200002030-00005.
4
Update on intestinal strictures.肠道狭窄的最新情况。
J R Soc Med. 1999;92 Suppl 37(Suppl 37):41-9. doi: 10.1177/014107689909237S08.
本文引用的文献
1
High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.高剂量胰酶补充剂与囊性纤维化患儿的纤维性结肠病
N Engl J Med. 1997 May 1;336(18):1283-9. doi: 10.1056/NEJM199705013361803.
2
Fibrosing colonopathy in cystic fibrosis: results of a case-control study.囊性纤维化中的纤维性结肠病：一项病例对照研究的结果
Lancet. 1995 Nov 11;346(8985):1247-51. doi: 10.1016/s0140-6736(95)91860-4.
Zotero 插件